Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

RA Prevention: A Trial of Methotrexate Vs. Placebo in Patients with Undifferentiated Arthritis

  |  

Conclusion: A one-year course of MTX delayed and prevented RA development in high-risk UA patients. This emphasizes the importance of adequate risk prediction in trials that aim to prevent RA.

Read the full article.

ADVERTISEMENT
SCROLL TO CONTINUE

Excerpted and adapted from:

Burgers LE, Allaart CF, Huizinga TWJ, et al. Clinical trials aiming to prevent rheumatoid arthritis cannot detect prevention without adequate risk stratification: Using a trial of methotrexate versus placebo in patients with undifferentiated arthritis as an example. Arthritis Rheumatol. 2017 May;69(5):926–931.

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    Pursue Remission

    Disease remission should be the goal for all rheumatologists treating childhood arthritis

    Case Report: RA Patient Suffers Methotrexate-Induced Cutaneous Lesions

    Methotrexate (MTX) remains the predominant medication used by rheumatologists to treat rheumatoid arthritis (RA). Doses of 7.5–25 mg per week with daily folic acid are generally prescribed. Despite its common use, MTX must be prescribed cautiously given the potential adverse effects when taken incorrectly or without folic acid supplementation. Cases of MTX-induced cutaneous ulceration have…